SAILLANT THERAPEUTICS

After preclinical development of new drug candidates, Saillant Therapeutics is interested in pursuing licensing agreements with established pharmaceutical and biotech companies to enable further clinical development, registration and commercialization... We are a biotechnology company located in The Netherlands developing promising small molecule based therapies. We have discovered a novel mechanism that is based on selective intra-cellular functional protein expression inhibition, selectively occurring only in stressed and infected cells. Based on this novel mode of action, our portfolio of leads was designed and developed. Preclinical results so far have shown promising results... Saillant Therapeutics B.V. is established in 2018 by Dr. Hamid el Azzouzi and Dr. Ad van Gorp. The team leverages its expertise in preclinical drug development to further validate and develop the promising therapeutic strategy of the ST-01 platform against acute ischemic stroke, heart failure (HF) and..

Also known as: Saillant, Saillant Therapeutics BV, Saillant Therapeutics Company